FDA clears Eagle device for selective laser trabeculoplasty
Key takeaways:
- The FDA cleared the Eagle device for selective laser trabeculoplasty.
- Laser energy is delivered in a noncontact procedure.
The FDA granted 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG glaucoma laser for selective laser trabeculoplasty, according to a press release from Belkin Vision.
“We anticipate that our technology will reduce the barriers that currently exist with conventional SLT by bringing an automated, noncontact direct-SLT treatment to market,” Daria Lemann-Blumenthal, CEO of Belkin Vision, told Healio. “The Eagle device has the potential to expand access to a larger number of ophthalmologists and thus patients in the United States.”
The device delivers laser energy in a noncontact procedure through the limbus to the trabecular meshwork without the use of a gonioscopy lens, the release said.
The Eagle device “automatically defines the target location [and] then applies the laser treatment sequence while the eye tracker compensates for any eye movement,” the release said. It also incorporates Direct-SLT technology to streamline the procedure.
“We’re currently planning a controlled rollout to key sites across the United States in 2024,” Lemann-Blumenthal told Healio. “We’re very much looking forward to making our solution available to more ophthalmologists and therefore more patients soon.”
Editor’s note: This article was updated on Dec. 12, 2023, to include comments from the CEO of Belkin Vision.
Collapse
Read more about